Second malignancies following radiotherapy for testicular seminoma.
Traditional treatment for testicular seminoma produces excellent survival. We report five, second non-testicular malignancies which occurred in a group of seminoma patients. A total of 79 men with primary testicular seminoma were available for analysis. All underwent a radical inguinal orchiectomy. Those with Stage I disease received adjuvant radiation therapy to the para-aortic and ipsilateral iliac nodes. The usual dose was 2500 cGy in 15 treatments. Stage II patients also received prophylactic mediastinal radiation therapy to a dose of 2500 cGy. None of the 51 Stage II patients died of tumour, whereas four of the 28 Stage II patients died of their disease. The median follow-up was ten years (range 4-25 years). The second malignancies seen were melanoma (2), myeloma, caecal adenocarcinoma, and retroperitoneal fibrosarcoma. All but one tumour developed within the radiation fields. Based on US SEER data for white males, only 1.5 cancers were expected, giving significantly greater (P = 0.04) relative risk. This observation lends support to observation, rather than elective treatment, in patients with Stage I testicular cancer.
Steinfeld
A D
AD
Division of Radiation Oncology, New York University Medical Center, NY 10016.
Shore
R E
RE
D004407:Dysgerminoma / Q000473:pathology / Q000532:radiotherapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009378:Neoplasms, Multiple Primary; D009381:Neoplasms, Radiation-Induced; D011878:Radiotherapy / Q000009:adverse effects*; D013736:Testicular Neoplasms / Q000473:pathology / Q000532:radiotherapy*